Abstract
“using anti-JAG1 blocking antibodies to specifically target colorectal cancer”
Financial & competing interests disclosure
We thank Instituto de Salud Carlos III (PIE15/00008 and PI16/00437)/FEDER and Generalitat de Catalunya (2017SGR135) for supporting this work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.